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Purpose—We report the toxicity profile and pharmacokinetic data of a schedule-dependent
chemoradiation regimen using pulsed low-dose paclitaxel for radiosensitization in a phase I study
for inoperable non-small cell lung cancer (NSCLC).
Methods and Materials—Paclitaxel at escalating doses of 15 mg/m2, 20 mg/m2, and 25 mg/m2
were infused on Monday, Wednesday, and Friday with daily chest radiation in cohorts of 6 patients.
Daily radiation (RT) was delayed for maximal G2/M arrest and apoptotic effect, an observation from
preclinical investigations. Plasma paclitaxel concentration was determined by High Performance
Liquid Chromatography (HPLC).
Results—Dose-limiting toxicities included 3/18 patients with grade 3 pneumonitis and 3/18 patients
with grade 3 esophagitis. There was no grade 4 or 5 pneumonitis or esophagitis. There was no grade
3 or 4 neutropenia, thrombocytopenia, anemia or neuropathy. For dose levels I (15 mg/m2), II (20
mg/m2), and III (25 mg/m2), the mean peak plasma level was 0.23 ±0.06 μM, 0.32±0.05 μM, and
0.52±0.14 μM, respectively; AUC was 0.44± 0.09 μM, 0.61± 0.1 μM, and 0.96± 0.23 μM,
respectively; and duration of drug concentration above 0.05 μM (t >0.05 μM) was 1.6± 0.3 hr, 1.9±
0.2 hr, and 3.0± 0.9 hr, respectively.
Conclusion—Pulsed low-dose paclitaxel chemoradiation is associated with low toxicity.
Pharmacokinetic data showed that plasma paclitaxel concentration above 0.05 μM for a minimum
of 1.6 hours was sufficient for effective radiosensitization.
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INTRODUCTION
Combination chemoradiation therapy has improved survival in patients with stage III
inoperable non-small cell lung cancer when compared with radiation treatment alone (1–9).
Despite the promising improvement by combined modality therapy, investigations using
various chemoradiotherapy combinations have yielded an average 5-year survival of less than
25%. While chemotherapy combinations have reached the plateau for non-small cell lung
cancer (10), intrathoracic disease control is even more disappointing with an average low rate
of control at 40–50% at best by radiographic criteria (1,4,6), and only 15%–17% control rate
by tumor biopsy through post-treatment bronchoscopy (4). Because locoregional failure can
serve as a continuous source of distant metastasis, improving chest disease control is critical
in the management of locally advanced NSCLC.
We previously conducted preclinical studies of the cell cycle and apoptotic effects of low-dose
paclitaxel on human lung cancer cell lines. We found that pulsing low-dose paclitaxel every
48 hours resulted in the restitution of G2/M cell cycle arrest, the most radiosensitive phase of
the cell cycle. The cell cycle effect started at approximately 4 hours after drug treatment, and
peaked at 24 hours. This was followed by a gradual recovery of G2/M effect after 36 hours,
and a return to baseline cell cycle distribution at 48 hours after treatment. In addition, paclitaxel
apoptotic effect peaked at 48 hours after in vitro treatment of lung cancer cell lines (12,13).
Clinical data from phase II investigation showed a 100% gross tumor response rate at 4 to 6
weeks post-therapy, with an absolute in-field tumor control rate of 97.6%, and a 3-year survival
rate of 21% (12,13).
To our knowledge, complete toxicity detail and pharmacokinetic profile using paclitaxel in
such a low dose range for radiosensitization has not been reported. The toxicity and
pharmacokinetic profiles of low-dose paclitaxel combined with chest irradiation, as well as the
clinical implications of this phase I study, will be discussed.
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Phase I Clinical Study of Pulsed, Low-dose Paclitaxel for Radiosensitization
A phase I clinical study of pulsed low-dose paclitaxel with daily fractionated thoracic
irradiation for inoperable NSCLC was conducted between 1998 and 2001 through a clinical
protocol approved by the University of Rochester Institutional Review Board. All patients had
given informed consent for participation. All patients were given standard premedications
(cimetidine, dexamethasone, and diphenhydramine) prior to paclitaxel infusion to reduce the
risk of hypersensitivity reactions. Low-dose paclitaxel was administered as a one-hour
intravenous infusion in the morning on Monday, Wednesday, and Friday. Thoracic radiation
(XRT) was given after 4:00 PM on the days when patients received chemotherapy to allow for
a minimum of a 4-hour interval for cell cycle progression. On Tuesday and Thursday when
there was no paclitaxel treatment, XRT was given any time after 11:00 AM.
The starting dose of paclitaxel was 15 mg/m2 with 5 mg/m2 increments for dose-escalation.
Dose-limiting toxicity was defined as grade 4 hematologic toxicity as well as grade 3 and 4
nonhematologic toxicity. Our initial plan was that escalation would be stopped when three or
more dose-limiting toxicities were observed at a dose in 6 patients. We maintained this schema
up to the third dose level (25mg/m2), where we found that the rates of tumor response and
shrinkage at all dose levels achieved maximum clinical effect in response to radiotherapy.
There were 6 to 7 patients treated at each dose level, with at least 5 or 6 patients completing
the correlative pharmacokinetic studies. All patients had CT-based treatment planning with
lung correction. The average XRT dose was 60–65 Gy to the gross disease and 45–58 Gy to
potential mediastinal microscopic disease given at 1.8 Gy daily fractions over 7.5 weeks. In
general, radiation portals encompassed gross disease with a 1.5 cm to 2 cm margin of
surrounding lung parenchyma.
Response and Toxicity Assessment
Blood counts, chemistry, and treatment related toxicities were monitored weekly during
chemoradiation treatment and at each follow-up visit. Toxicity was scored according to
National Cancer Institute Common Toxicity Criteria (NCI CTC) Version 2.0 (14). All patients
had follow-up chest CT scans at 4 to 6 weeks post-therapy and serial follow-up CT scans at 3-
month intervals. Response to therapy was assessed according to two- dimensional radiological
tumor measurements. Clinical Complete Response (CR) was defined as complete
disappearance of all evidence of tumor. Partial Response (PR) was defined as a tumor decrease
by at least 50%. Stable Disease (SD) was defined as no change in measurable disease or changes
that were too small to meet the requirements for partial response or progression. Progressive
Disease or Relapse was defined as the development of any new areas of malignant disease that
were measurable or palpable, or an increase by more than 25% in any pretreatment area of
measurable disease.
Pharmacokinetic Measurements
All patients had intravenous catheters inserted in both of their arms. One catheter was used for
the infusion of paclitaxel while the other was used for blood sample collection. A total of 17
samples from each patient were collected in green-top, heparinized vacutainers (2.5 mL to 3.0
mL of blood). Blood was collected prior to paclitaxel infusion and at the following time points
from the start of infusion: 10 minutes, 15 minutes, 1 hour, 1 hour and 10 minutes, 1 hour and
15 minutes, 1 hour and 30 minutes, 1 hour and 45 minutes, 2 hours, 2 hours and 30 minutes,
4 hours, 6 hours, 8 hours, 16 hours, 24 hours, and 30 hours. Samples were immediately placed
on ice and centrifuged at 1,000 × g to produce plasma. Plasma was immediately frozen and
stored at −20 °C until assayed for paclitaxel concentration.
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Paclitaxel concentration in plasma was determined by HPLC, using modifications of the
method by Jamis-Dow, et al (15). Briefly, 0.5 mL of plasma was mixed with 5μL of 50 μM
cephalomannine internal standard (Developmental Therapeutics Program, National Cancer
Institute, Bethesda, MD) and applied to a Spe-ed C18 solid phase extraction device (Applied
Separations, Lehigh Valley, PA), which had been preconditioned with sequential washings of
1 mL acetonitrile and 1 mL distilled water. After application of plasma, the devices were
washed with 3 mL distilled water, and paclitaxel and internal standard were eluted from the
Spe-ed with 2 mL acetonitrile. The eluates were evaporated to dryness under nitrogen with an
N-evap (Organomation Associates, South Berlin, MA). The dried residues were reconstituted
in 200 μL of the mobile phase described below, and 150 μL were injected onto the HPLC
system.
HPLC system included a Hewlett Packard (Palo Alto, CA) 5 μm Hypersil ODS (100 × 4.6 mm)
column protected with a Brownlee Newguard precolumn cartridge (Applied Biosystems Inc.,
Foster City, CA). The isocratic mobile phase, which consisted of acetonitrile: distilled,
deionized water (45:55, v/v), was delivered at a low rate of 1.0 mL/min with a Waters model
510 pump (Waters Chromatography, Milford, MA). Column effluent was monitored at 230
nm with a Spectroflow 757 absorbance detector (AB1 Analytical, Kratos Division, Ramsey,
NJ). Under each peak eluted, the detector signal was processed with a Hewlett Packard model
3396 integrator. Paclitaxel concentration in each sample was calculated by determining the
ratio of paclitaxel peak area to that of the corresponding internal standard peak and comparing
that ratio to a concomitantly performed standard curve prepared in the appropriate matrix. The
lower limit of quantization was 0.010 μM in human plasma. The assay was linear between
0.010 and 200 μM paclitaxel. The coefficient of variability for the analysis was ≤ 15% with
regard to both intra-day analysis of any concentration on the standard curve or inter-day
comparison of standard curves.
Pharmacokinetic analysis was conducted using the program ADAPTII. A previously described
3-compartment non-linear model was fit to the plasma paclitaxel concentration versus time
profile of each patient (16). In this analysis, the model was fit to the data using Bayesian
estimation with previously described population means and variances as prior information for
each pharmacokinetic parameter estimated by the model as described (16).
RESULTS
Patient characteristics
Seventeen patients completed the 7.5 weeks of chemoradiation, and one patient completed 6
weeks of the planned chemoradiation before evidence of distant disease progression. Patient
characteristics are shown in Table 1. The definition of “inoperable” non-small cell lung cancer
in this study includes the majority of stage III non-small cell lung cancer, who are not operable
due to tumor stage, as well as a smaller population with stage I–II disease deemed inoperable
by the thoracic surgeons due to poor pulmonary functions. Specifically, two of the four patients
were deemed inoperable for pneumonectomy, which included one patient of stage II disease
with a FEV 1 of 1.53 L and the other patient of stage II disease with a FEV 1 of 2.38 L. The
other two of the four patients were deemed inoperable for lobectomy, which included one
patient of stage I disease with a FEV1 of 0.75 L and the other of stage I disease with a FEV1
of 1.03 L.
Toxicity profiles by dose levels
With 6 patients at each dose level, toxicity was recorded and evaluated. When there was <3/6
patients with grade 3 and above nonhematologic toxicity, or grade 4 hematologic toxicity, the
dose was escalated to the next level. As shown in Table 2, hematologic toxicity was mild, being
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either grade 1 or 2. Non-dose limiting grade 3 lymphopenia was seen for all dose levels and is
an expected side effect from radiation treatment. Table 3 shows the nonhematologic toxicities
for all 3 dose levels. There was no peripheral neuropathy. Nausea/vomiting, fatigue, weight
loss, or tachycardia was only grade 1 or 2. There were no grade 4 nonhematologic toxicities.
Grade 3 pneumonitis occurred in 3/18 patients with one at each dose level. Grade 3 esophagitis
occurred in 3/18 patients with 1 at dose level I, 2 at dose level II, and none at dose level III.
Grade 2 alopecia was observed in 3 patients at dose level III but not at dose level I or II. There
was no grade 3 and 4 dose-limiting toxicity (DLT) for dose levels I and II, and thus dose
escalation continued to level III. At dose level III, 3 patients showed grade 2 alopecia and 2
patients showed grade 3 anemia. By the time the third dose level completed, the tumor response
rate was analyzed, which showed equivalent gross tumor shrinkage and response for all dose
levels, i.e., 100% response rate and 87% tumor shrinkage for all doses (Table 4). It was deemed
of no further benefit to continue dose escalation as the maximal clinical effect of local tumor
response to radiotherapy had been achieved.
Gross tumor shrinkage by dose levels
The gross tumor response was measured from chest CT scans obtained at 4 to 6 weeks
postchemoradiation and compared with pretreatment tumor dimensions on CT. The overall
response rate was 100% with 12% (2/17 patients) complete response, and 88% (15/17 patients)
partial response. Although there was difference in stage distribution in term of early stage (stage
I and II) of patients of each dose level, but the difference did not impact on the response rate.
Dose level I had one stage II patient (1/6 = 17%) and five stage III patients. Dose level II had
two stage II, and 1 stage IIB patients (3/6 = 50% for stage I and II) and three stage III patients.
Dose level III had all stage III non-small cell lung cancer and no stage I–II patients. Despite
the differences in the stage distribution of these stage I–II patients, the degree of tumor
shrinkage did not differ, and the overall tumor response rate (CR + PR) was all 100% for all
three dose levels, as shown in Table 4.
Pharmacokinetics
Pharmacokinetic analyses were conducted in 7 patients treated at 15 mg/m2, 5 patients at 20
mg/m2, and 6 patients at 25 mg/m2. Figure 1A demonstrates a representative plasma paclitaxel
concentration versus time curve of low-dose paclitaxel given as a one-hour intravenous
infusion. With dose escalation there was an increase in the peak plasma concentration (Figure
1B), the area under the plasma paclitaxel versus time curve (AUC) (Figure 1C), and the duration
for which paclitaxel concentration was above 0.05 μM (Figure 1D). Table 5 summarizes the
pharmacokinetic profiles of the 3 dose levels.
DISCUSSION
Improving chest disease control can improve survival of patients with stage III NSCLC. The
best example is the randomized phase III study incorporating low-dose sensitizing cisplatin to
chest radiation conducted by Schaake-Koning et al (1). There were three treatment arms of this
European study: radiotherapy alone, radiotherapy with weekly cisplatin (30 mg/m2), and
radiotherapy with daily cisplatin (6 mg/m2). There was no treatment arm administering
systemic doses of cisplatin; thus the improved survival outcome of this study is through
improving chest tumor control by enhanced radiation effect. We report that the daily cisplatin
and radiotherapy arm yielded the best survival rate, supporting the idea that improving chest
disease control will improve survival. In recent years, many other chemotherapeutic agents
have been delivered as sensitizing agents to improve radiation effect, including the taxanes,
gemcitabine, vinorelbine, and topoisomerase (17,18). Among these, paclitaxel has been a
favored drug due to its ability to arrest cells at the G2/M interphase in the cell cycle. While
several different dose schedules of paclitaxel chemoradiation regimens in the treatment of
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inoperable NSCLC have been reported, the optimal schedule in delivering paclitaxel
chemoradiation combination remains unclear.
The pharmacokinetics of full-dose paclitaxel at much higher concentrations of 135 mg/m2, 175
mg/m2 and 225 mg/m2 was previously investigated by Gianni et al (16). These investigators
reported important pharmacokinetic characteristics and the impact on bone marrow
suppression by the differences of drug concentrations and infusion time. It was found that the
infusion time affected the peak plasma concentration as well as the duration of the peak
concentration of the drug. The shorter infusion time of 3 hours in their study resulted in a higher
plasma peak concentration of paclitaxel, which was followed by a rapid decline of plasma drug
concentration. The longer infusion time of 24 hours resulted in a relatively lower plasma peak
concentration, but a much longer duration of a plateau during this time period. They found that
the 24-hour infusion time with a longer plateau concentration above 0.05μM (t>0.05μM)
resulted in higher incidences of neutropenia than the 3-hour infusion, thus the duration of
plasma paclitaxel concentration that was higher than 0.05 μM (t>0.05μM) was directly
proportional to the risk of neutropenia.
We report the details of the toxicity profile with low-dose paclitaxel delivered in a pulsed
schedule every 48 hours, and the pharmacokinetic properties of radiosensitizing paclitaxel in
the very low dose range of 15 mg/m2 to 25 mg/m2. We chose the one hour infusion time with
the intention of applying low-dose paclitaxel primarily for radiosensitization, thus an
immediate peak level in rendering cancer cells into the G2/M phase of the cell cycle followed
by a rapid decline would be ideal and would be at low risk of hematologic toxicity.
The response rate of our study was compared with chemoradiation using full-dose
chemotherapy (13). From the perspective of radiosensitization, the clinical outcome of our
phase I/II study was quite satisfactory with a 100% response rate and a 97.6% chest disease
control rate. This is a significant improvement when compared with other reported studies for
locally advanced NSCLC, where local control is less than 50% at best.
The radiation dose required to control human epithelial tumors larger than 5 cm in diameter is
approximately 80 to 100 Gy (19). As for inoperable NSCLC, it was suggested that the radiation
dose required for a 50% probability of tumor control was approximately 85 Gy (20,21). For
patients treated with definitive radiation for small T1 and T2 inoperable tumors of NSCLC,
the local control rates were only 30% to 60% with radiation dose at approximately 60 Gy
(22–24). Normal tissue tolerance of the esophagus, trachea, bronchi, lung parenchyma, and
heart is a primary dose-limiting factor for chest radiotherapy, thus the radiation doses for
inoperable NSCLC have been kept below 70 Gy to avoid complications. Most patients in this
phase I study had large, inoperable tumors and received only 60 Gy to 65 Gy radiation to gross
tumor, yet the tumor shrinkage was very encouraging (82% to 84%), supporting the fact that
schedule-dependent pulsed paclitaxel chemoradiation is an effective radiosensitizing regimen.
Furthermore, the lack of dose response of sensitizing paclitaxel supports that pushing for dose-
limiting toxicity may not be the optimal goal for radiosensitization chemotherapy. The long-
term follow-up data showed that there was one in-field local tumor failure in patients treated
at dose level I in the phase I study of this regimen. There was no in-field gross tumor failure
at dose level II and level III. Because every follow-up chest CT scan was reviewed personally
by the investigator and the medical oncologist, we could comment that there was, however,
chest failure presenting as separate pulmonary nodules in other lobes or other lung (outside of
initial radiation ports). These were discrete pulmonary nodules in other lobes or contralateral
lung, thus were metastatic nodules and not local failure. A separate manuscript has been
prepared to address the pattern of failure of this regimen, and these points will be discussed in
detail.
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The pharmacokinetic study revealed important characteristics of sensitizing paclitaxel. The
short infusion time of one hour resulted in a short peak plasma level of paclitaxel, while
achieving the effective radiosensitization. Our data support that a short interval (between 1.5
hours and 3 hours) of plasma drug concentration between 0.05μM and 0.23μM and a very low
concentration of paclitaxel is sufficient for effective radiosensitization. Since our
chemoradiation schedules were designed to deliver radiation during cell cycle arrest, it is not
clear that will be seen without an appropriate delay of 4 hours on the days chemotherapy is
administered. The clinical finding was consistent with our preclinical in vitro observation of
lung cancer cell lines in that a relatively short duration of exposure of cancer cells to low doses
of paclitaxel was sufficient for radiosensitization (12,13). The toxicity profile of this phase I
study is compatible with published pharmacokinetic information of full-dose paclitaxel (16)
in that the risk of grade 3 and 4 neutropenia in our study was low because of the 1.5 to 3 hour
duration of plasma paclitaxel concentration above 0.05 μM (t>0.05μM). We saw no grade 2
neutropenia and thrombocytopenia, without any grade 3 or 4 hematologic toxicities. Grade 3
anemia was only seen in 3 patients at the level III dosing of 25 mg/m2. The peak plasma level,
AUC and t>0.05 μM increased with dose-escalation. The increase in magnitude of these
parameters was small, and there did not appear to be any significant increase in the in the risk
of nonhematologic toxicity such as grade 3 pneumonitis and esophagitis. The overall rates of
grade 3 pneumonitis and esophagitis for all patients in this phase I study were much lower than
reports using other dose schedules of paclitaxel and radiation (17,25,26). One may argue that
the 4 patients with stage I–II diseases might have been treated with smaller radiation ports,
which might have contributed to the low rates of esophagitis and/or pneumonitis. We reviewed
the radiation ports of these 4 patients and did not find major differences in the size of radiation
ports. These patients were treated during the era when prophylactic mediastinal irradiation had
been a common practice for stage III and some stage II patients. Our review showed that the
2 stage II patients had radiation ports encompassing the lung lesion, the ipsilateral hilar and
the mediastinum. The 2 stage I patients (both at dose level II) had central lesions and had
radiation ports encompassing the lung lesion, the ipsilateral hilar region, and the adjacent
mediastinal region due to the proximity of the primary lesions to the mediastinum. Our data
in these patients did not show a significant variation in the radiation field size of stage I/II
patients vs. stage III patients, thus the data could not reflect the impact on the risk of esophagitis
or pneumonitis in relation to radiation field size.
In summary, schedule-dependent pulsed low-dose paclitaxel chemoradiation is an effective
regimen for improving local tumor control and is associated with very low rates of toxicity.
We found that all three of the dose levels resulted in a similar degree of tumor shrinkage while
there appeared to be a trend of increasing toxicity with dose-escalation. The pharmacokinetics,
clinical efficacy, and toxicity demonstrated in this trial suggest that effective radiosensitization
may be achieved with sensitizing chemotherapy at lower dose levels than previously published.
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Figure 1. Pharmacokinetics of low-dose paclitaxel
1A: Plasma paclitaxel concentration versus time. 1B: Peak plasma level-- relationships of drug
concentration and pharmacokinetic properties. 1C: Area under the curve (AUC). 1D: Duration
of plasma drug concentration above 0.05μM (t>.05μM). There is a proportionate increase in
peak plasma level, AUC, and t>.05μM with paclitaxel infusion from dose level I to level III.
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Table 2
Hematologic Toxicity
Level I: 15 mg/m2 (n=6) Grade 1 Grade 2 Grade 3 Grade 4
 anemia 1 2 0 0
 neutropenia 1 0 0 0
 thrombocytopenia 2 0 0 0
 lymphopenia 0 0 6 0
Level II: 20 mg/m2 (n=6)
 anemia 4 1 0 0
 neutropenia 0 0 0 0
 thrombocytopenia 1 0 0 0
 lymphopenia 0 0 6 0
Level III: 25mg/m2 (n=6)
 anemia 3 1 2 0
 neutropenia 1 0 0 0
 thrombocytopenia 0 0 0 0
 lymphopenia 0 0 6 0
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Table 3
Non-hematologic Toxicity
Level I: 15 mg/m2 (n=6) Grade 1 Grade 2 Grade 3 Grade 4
 pneumonitis 0 0 1 0
 esophageal 2 3 1 0
 nausea/vomiting 0 1 0 0
 weight loss 1 0 0 0
 fatigue 1 3 0 0
 tachycardia 1 0 0 0
 alopecia 0 0 0 0
 neuropathy 0 0 0 0
Level II: 20mg/m2 (n=6)
 pneumonitis 0 0 1 0
 esophageal 0 4 2 0
 nausea/vomiting 1 0 0 0
 weight loss 0 1 0 0
 fatigue 1 4 1 0
 tachycardia 0 1 0 0
 alopecia 0 0 0 0
 neuropathy 0 0 0 0
Level III: 25mg/m2 (n=6)
 pneumonitis 0 0 1 0
 esophageal 2 4 0 0
 nausea/vomiting 0 0 0 0
 weight loss 1 0 0 0
 fatigue 2 3 0 0
 tachycardia 1 0 0 0
 alopecia 0 3 0 0
 neuropathy 0 0 0 0
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Table 4
Tumor shrinkage at 4–6 weeks after completion of therapy
Paclitaxel dose levels Tumor shrinkage Response
CR PR
I, 15 mg/m2 (n=6) 82% ± 14% 2 (33%) 4 (67%)
II, 20 mg/m2 (n=6) 84% ± 16% 0 6 (100%)
III, 25 mg/m2 (n=6) 84% ± 27% 0 4 (100%)
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Table 5
Summary of pharmacokinetic characteristics of paclitaxel (mean ± S.D.)
Dose levels Peak Concentration (μM) AUC (μM × hr) T > 0.05 μM (hr)
Level I (15 mg/m2 ) 0.23 ± 0.06 0.44 ± 0.09 1.56 ± 0.27
Level II (20 mg/m2) 0.32 ± 0.05 0.61 ± 0.1 1.86 ± 0.21
Level III (25 mg/m2) 0.52 ± 0.14 0.96 ± 0.23 2.94 ± 0.94
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